Skip to content
Screener

Total Equity at other companies

Incyte logo
IncyteINCY
$6.34B+52.1%
BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN
$6.32B+4.9%
UroGen Pharma logo
UroGen PharmaURGN
-$132.4M-41.8%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
-$2.28B-38.2%
ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
$323.98M+60.0%
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
$41.62M-80.6%

Other financials

Income statement

See full
Operating income-$42.0M-31.9%
Net income-$39.3M-39.6%
EPS (diluted)-$0.64-36.2%

Balance sheet

See full
Cash & equivalents$85.0M-15.7%
Total debt$5.7M-6.9%
Total assets$412.0M+20.0%

Cash flow

See full
Operating cash flow-$32.6M-27.9%
CapEx$88.0K+529%
Free cash flow-$32.7M-28.2%

Valuation

See full
Market cap$1.61B+174%
Enterprise value$1.53B+210%

Returns & leverage

See full
Return on equity-36.9%+21.1pp
Debt / equity0.0×
Current ratio20.5×-2.3×

Where this comes from

Reported directly by Tyra Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:StockholdersEquity.

The source filing: Tyra Biosciences, Inc.’s 10-Q, filed May 13, 2026.

Filed
May 13, 2026, 8:03 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-220645
Line itemMarch 31, 2026December 31, 2025
Stockholders’ equity:
Preferred stock, $0.0001 par value; 50,000,000 shares authorized at March 31, 2026 and December 31, 2025; no shares issued and outstanding at March 31, 2026 and December 31, 2025
Common stock, $0.0001 par value; 500,000,000 shares authorized at March 31, 2026 and December 31, 2025; 59,469,687 and 53,706,357 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively65
Additional paid-in capital798,025630,037
Accumulated other comprehensive income107393
Accumulated deficit(410,563)(371,258)
Total stockholders’ equity387,575259,177
Total liabilities and stockholders’ equity$412,040$282,609

Item 1. Condensed Financial Statements

FAQ

What is Tyra Biosciences, Inc.'s total equity?
Tyra Biosciences, Inc. (TYRA) reported total equity of $387.58M in Q1 2026.
How has Tyra Biosciences, Inc.'s total equity changed year-over-year?
Tyra Biosciences, Inc.'s total equity increased by 19.8% year-over-year, from $323.53M to $387.58M.
What is the long-term trend for Tyra Biosciences, Inc.'s total equity?
Over 5 years (2020 to 2025), Tyra Biosciences, Inc.'s total equity has grown at a 80.2% compound annual growth rate (CAGR), from -$13.64M to $259.18M.
What does total equity mean?
Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.

Ask your AI about Tyra Biosciences, Inc.'s total equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude